 |
 |
|
|
 |
|
Acorda Therapeutics, Inc.
Acorda Therapeutics,
Inc. develops therapeutic products for spinal cord injury ("SCI")
and other central nervous system disorders such as multiple sclerosis
(MS). Acorda is focusing its initial development efforts on a range
of therapeutics for individuals with chronic, or long term, SCI. Currently,
there is no therapy that improves neurological function in chronic
SCI patients.
Co-Investors: MDS, MPM, Easton Hunt
|
|
All Investments
Active
Investments
Exited
Investments |
 |
|
Amnis
Amnis is developing a high-speed
cell analysis technology for clinical and research applications (diagnostics-
cancer, genetic based disease, therapeutics- treatment monitoring).
The company is working with two leading academic institutions and
with a leading pharmaceutical to leverage the technology into drug
discovery applications.
Co-Investors: TVM, Orbi-Med, Hillman, WRF Capital, Sunshine Capital
|
|
|
| |
|
Ampla Pharmaceuticals
Ampla Pharmaceuticals
- stealth mode biotechnology company.
Co-Investors: Advent International and Crabtree Ventures
|
|
|
 |
|
Blue Heron
Blue Heron is a biotechnology
tools company, which has developed proprietary technology to rapidly
synthesize custom engineered genes. One of the major bottlenecks in
genetic research for pharmaceutical and agricultural companies is
the time and effort required to prepare genes for detailed analysis.
Blue Heron's outsourced service enables researchers to go directly
from planning molecules on the desktop, ordering them over the web,
to testing them in the lab. Blue Heron targets difficult to clone
genes and variants that biotech companies are unable to produce themselves.
Co-Investors: Crabtree Ventures, Invitrogen, Pacific Rim Ventures,
Dr. Lee Hood
|
|
|
 |
|
Calypso Medical Technologies, Inc.
Calypso
Medical Technologies, Inc. is medical device company headquartered
in Seattle, Washington. The company is developing innovative tools
and therapies for the oncology market that address unmet needs in
radiation therapy. Calypso has assembled an experienced management
team, world class biomedical engineers and scientists, and an extensive
scientific advisory board.
Co-Investors: Frazier, Versant, RiverVest, Utah
|
|
|
 |
|
Cara Vita
Cara Vita has developed a
cost-effective, health maintenance approach to caring for the chronically
frail elderly in non skilled settings. While principally a residential
care provider, Cara Vita has integrated private home health and day
care programs into its facilities to provide an alternative for those
seniors and their families who are not yet prepared for a residential
program. Cara Vita is built on a care model designed to enhance resident
health and allow high acuity residents to remain in Cara Vita's facilities
longer and age in place gracefully.
Co-Investors: Delphi, Live Oak, Cordova
|
|
|
 |
|
Cardax
Cardax Pharmaceuticals is a
drug discovery and development company targeting large unmet medical
needs where inflammation plays a crucial and often newly defined pivotal
role. The Company’s first product targets cardiovascular disease.
Cardax Pharmaceuticals was spun out from Hawaii Biotech in May 2006.
Co-Investors: Technology Partners, Arcadia Holdings, Advantage Capital
|
|
|
 |
|
ClearMedical, Inc.
ClearMedical, Inc.
is a Bellevue, Washington based company that significantly reduces
healthcare costs by delivering specialized recycling technology for
disposable medical devices. They provide comprehensive medical device
reprocessing services and meet all quality standards required by regulatory
agencies.
Co-Investors: BDV, Eaglestone
|
|
|
 |
|
Corus Pharma
Corus Pharma, a Seattle-based
specialty pharmaceutical development company, is committed to developing
and obtaining regulatory approvals of products for respiratory and
infectious diseases that can help provide improved health and superior
quality of life.
Co-Investors: MDS, Novo, JP Morgan
|
|
|
 |
|
Guava Technologies, Inc.
Guava Technologies,
Inc. is a privately-held biotechnology company located in Hayward,
California that develops, manufactures and markets unique, high-impact
cellular analysis systems for the life science research marketplace.
Guava's patented technology has revolutionized the way scientists
perform cell-based analysis.
Co-Investors: HLM, MDS, ProQuest, Abingworth , St. Paul
|
|
|
 |
|
Hawaii Biotech, Inc.
Hawaii Biotech,
Inc. is a leader in the development of vaccines to protect from emerging
infectious disease, including avian (pandemic) Influenza, West Nile
encephalitis, and Dengue Fever. Hawaii Biotech's proprietary manufacturing
platform, which exploits recombinant DNA technology to produce commercially
scaleable, ultra-high quality vaccine components, is uniquely suited
to produce commercially-viable vaccines in the quantities and timeframe
needed to address emerging infectious diseases.
Co-investors: Technology Partners, Arcadia Holdings, Advantage Capital
|
|
|
 |
|
HealthHelp
HealthHelp is a highly successful national radiology quality assurance
program manager that has created significant savings and return
on investment for payers, by decreasing the cost of diagnostic imaging
while increasing the quality of care enrollees receive. HealthHelp
has become the leader in radiology benefit management by providing
innovative, evidence-based programs that provide physicians with
the evidence-based clinical information and support they need when
ordering radiology exams, help managed care organizations identify
radiology and anesthesiology claims paid in error and adopt new
payment policies, educate plan enrollees and their physicians about
the effects of radiation by providing them with the tools to make
informed decisions, assist enrollees in selecting the most cost-effective,
most convenient, and highest quality imaging centers; and ensure
quality imaging through facility and physician evaluations that
use nationally accepted standards.
Co-investors: Essex Woodlands, Sarofim Adler affiliates,
Ed Mashek, Management
|
|
|
 |
|
MediQuest
MediQuest Therapeutics is a privately held specialty
pharmaceutical company headquartered in Bothell, Washington.
MediQuest Therapeutics, Inc. (MediQuest) is a specialty
pharmaceutical company developing first- and best-in-class topical
therapies in late-stage clinical development to treat patients suffering
from inflammatory and infectious diseases. Using a proprietary drug
delivery technology, MediQuest can deliver a topical, non-systemic
therapy through thickened or diseased skin and nails. The Company's
innovative therapeutic treatments and proprietary drug delivery
have generated a robust product pipeline aimed at treating inflammatory/infectious
diseases and satisfying an unmet medical need.
|
|
|
 |
|
Napo Pharmaceuticals (LSE: NAPL)
Napo
Pharmaceuticals, Inc. is focused on developing and commercializing
proprietary pharmaceuticals for the global marketplace, in collaboration
with local partners, in order to address major global unmet medical
needs in developed and developing countries. Napo is currently developing
crofelemer, which is in various stages of clinical development for
four distinct product indications, including one product in Phase
III, two in Phase II and one in Phase I clinical trials.
Co-Investor: Vulcan
|
|
|
 |
|
National Healing
National Healing is
a disease management company with a focused expertise in managing
wound treatment centers inside client hospitals. The Company has established
50 clinics with hospital clients including: Columbia, Quorum, MedCath,
and several independent hospitals. In their centers, National Healing
provides high-quality, cost-effective methodologies to expedite the
healing of wounds and reduce inpatient stays.
Co-Investors: Sole Institutional Investor
|
|
|
 |
|
PLx Pharma Inc.
PLx Pharma Inc. is developing
the next generation of non-steroidal anti-inflam-matory drugs (NSAIDs)
for arthritis and cardiovascular markets. PLx has developed novel
formulations of NSAIDs with dramatically reduced gastrointestinal
(GI) toxicities. The Company's lead product, Ibuprofen-PC has completed
Phase III clinical trials, and the GI safety of the formulation is
currently being tested. The formulation platform appears applicable
to increase the therapeutic index of any NSAID.
Co-investors: MediGen Group
|
|
|
 |
|
Raven Biotechnologies
Raven Biotechnologies,
Inc. is a privately held company that develops monoclonal (MAb)-based
therapeutics, discovery tools, and technologies using unique, tissue-specific
stem (i.e. progenitor) cells as inputs. While the company's therapeutic
and drug-target discovery platform is applicable to many diseases,
Raven is currently focused on MAb therapies for cancer.
Co-Investors: Bear Stearns Health Innoventures, Biogen Idec New Ventures,
USVP, CMEA, Vulcan, H&Q
|
|
|
 |
|
Targeted Growth
Targeted Growth, Inc. was founded in 1999
with a goal of developing technologies that would increase the productivity
of existing farmland and create new crops for use on land otherwise
unsuitable for agriculture. Today, Targeted Growth is a global leader
in bioscience, having developed technologies that both increase seed
size and yield in major biofuel crops. The company has strategic partnerships
with leading researchers and agribusinesses around the world. Targeted
Growth is based in Seattle, Wash. with labs in Seattle, Saskatchewan,
Ottawa and New Brunswick. Co-investors: GrowthWorks,
Investment Saskatchewan, Capricorn Management, AllianceBernstein,
WRF Capital
|
|
|
 |
|
Tepha
Tepha is a Cambridge, MA based
medical device and biomaterial manufacturer that is developing resorbable
materials for medical uses. The company manufactures polyhydroxybutyrate
biopolymers synthesized in bacteria that have a number of advantages
over current materials including absorbability and tissue friendliness.
In addition, these polymers are comprised of building blocks that
metabolize into naturally occurring molecules. These biopolymers can
be manufactured into a number of different products from sutures and
hernia meshes to heart valves and ligaments.
Co-Investors: Vertical, Novartis
|
|
|
 |
|
WellPartner
Wellpartner is an innovative provider of
comprehensive pharmacy fulfillment solutions. It delivers straightforward,
transparent and personalized pharmacy fulfillment for individuals
with chronic and recurring medication needs who are beneficiaries
of commercial and Medicaid health plans, pharmacy benefit administrators,
or the health care safety-net nationwide. The Company's extensive
experience with the federal 340B drug discount program, combined with
its expanding pharmacy fulfillment options, has enabled Wellpartner
to become the largest provider of contract pharmacy programs in the
U.S.
Wellpartner has been recognized as one of the fastest growing private
companies in the U.S. and was recently ranked #119 in Inc. Magazine’s
list of the 500 fastest growing companies in the U.S. for 2006.
Co-Investors: Mediphase, Buerk Dale Victor, Scorpion, Burrill & Company, Apposite Capital
|
|
|
|
|
|
|
|
|
|
